AR and prostate cancer: The emergence of constitutively active androgen receptor (AR) splice variant AR‐V7 poses a formidable challenge in treating prostate cancer, as it lacks the ligand binding region targeted by androgen‐deprivation therapies such as enzalutamide and abiraterone.